{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:30:38Z","timestamp":1786480238365,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,12]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Kidney function was independently associated with free drug concentration; the latter concentration was higher in patients with a lower eGFR.<\/jats:p>\n <\/jats:list-item>\n \n The conformational changes in albumin induced by carbamylation may alter its binding capacity to vitamin K antagonists.<\/jats:p>\n <\/jats:list-item>\n \n The results on the accumulation of free fraction of drugs in patients with low eGFR may be applicable to other drugs that are bound to plasma proteins.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n The metabolic disturbances associated with CKD might alter drug distribution, decrease albumin drug binding, and thus increase the free (unbound) drug concentrations. Uremic toxins (UTs) can affect the pharmacokinetic or pharmacodynamic activity of certain drugs. Vitamin K antagonists (VKAs) are interesting candidates for the evaluation of potential interactions between UTs and drugs. The primary objective of this study was to investigate the association between free VKA concentrations and the eGFR. Furthermore, we sought to determine whether this relationship was mediated by protein carbamylation (measured by homocitrulline levels) and\/or the accumulation of protein-bound UTs (PBUTs).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this prospective cross-sectional study, 389 adult patients treated with VKA were included between May 2021 and June 2023. Levels of free VKAs, total VKAs, homocitrulline, and PBUTs were assayed using liquid chromatography-tandem mass spectrometry. We used a linear regression model to explore the association between kidney function and free VKA levels and mediation analyses to determine whether the association between kidney function and free VKA levels was mediated (at least partly) by PBUTs and\/or protein carbamylation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Patients with an eGFR <40 ml\/min per 1.73 m\n 2<\/jats:sup>\n or those on chronic hemodialysis had lower total VKA levels, higher free VKA levels, and thus a higher of free\/total VKA ratio than those with an eGFR \u226540 ml\/min per 1.73 m\n 2<\/jats:sup>\n . Kidney function was independently associated with free VKA levels (\n \u03b2<\/jats:italic>\n 1<\/jats:sub>\n =0.31 [0.19 to 0.42],\n P<\/jats:italic>\n < 0.001). Twenty-one percent (95% confidence interval, 1% to 35%) of the association between kidney function and free VKA levels was mediated by homocitrulline, but not by PBUTs.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our results showed that a low kidney function was associated with an elevation in the VKA free drug fraction. This association was independent of blood albumin levels and appeared to be partly mediated by protein carbamylation.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000000862","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:04:48Z","timestamp":1750334688000},"page":"2145-2156","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Interactions between Drugs and Metabolic Disturbances in CKD"],"prefix":"10.34067","volume":"6","author":[{"given":"Touria","family":"Mernissi","sequence":"first","affiliation":[{"name":"MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France"},{"name":"Toxicology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-6563","authenticated-orcid":false,"given":"St\u00e9phane","family":"Jaisson","sequence":"additional","affiliation":[{"name":"MEDyC Unit, CNRS, Reims University Medical Center (Department of Biochemistry-Pharmacology-Toxicology), University of Reims Champagne-Ardenne, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9853-3266","authenticated-orcid":false,"given":"Pierre","family":"Spicher","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Kamel","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8945-664X","authenticated-orcid":false,"given":"Ana\u00efs","family":"Okwieka","sequence":"additional","affiliation":[{"name":"MEDyC Unit, CNRS, Reims University Medical Center (Department of Biochemistry-Pharmacology-Toxicology), University of Reims Champagne-Ardenne, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8536-9733","authenticated-orcid":false,"given":"Julien","family":"Demagny","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amiens-Picardie University Medical Center, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France"},{"name":"Department of Nephrology, Dialysis and Transplantation, Amiens-Picardie University Medical Center, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-5567","authenticated-orcid":false,"given":"Sol\u00e8ne M.","family":"Laville","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France"},{"name":"Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-9212","authenticated-orcid":false,"given":"Sandra","family":"Bodeau","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France"},{"name":"Toxicology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-9006","authenticated-orcid":false,"given":"Sophie","family":"Liabeuf","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France"},{"name":"Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"12","key":"B1-20260109","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/ckj\/sfad241","article-title":"Drugs with a negative impact on cognitive function (part 1): chronic kidney disease as a risk factor","volume":"16","author":"Liabeuf","year":"2023","journal-title":"Clin Kidney J."},{"issue":"2","key":"B2-20260109","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semnephrol.2014.02.008","article-title":"Clinical Studies and chronic kidney disease: what did we learn recently?","volume":"34","author":"Liabeuf","year":"2014","journal-title":"Semin Nephrol."},{"issue":"5","key":"B3-20260109","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int."},{"issue":"11","key":"B4-20260109","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1681\/ASN.2006010035","article-title":"Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure","volume":"17","author":"Michaud","year":"2006","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B5-20260109","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1124\/jpet.106.112631","article-title":"Down-regulation of intestinal drug transporters in chronic renal failure in rats","volume":"320","author":"Naud","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"issue":"8","key":"B6-20260109","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1124\/dmd.112.045245","article-title":"Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease","volume":"40","author":"Velenosi","year":"2012","journal-title":"Drug Metab Dispos."},{"issue":"3","key":"B7-20260109","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1248\/bpb.b20-00929","article-title":"Effects of uremic toxins on the binding of aripiprazole to human serum albumin","volume":"44","author":"Nishi","year":"2021","journal-title":"Biol Pharm Bull."},{"issue":"3","key":"B8-20260109","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1681\/ASN.2017030361","article-title":"Indoxyl sulfate upregulates liver P-Glycoprotein expression and activity through aryl hydrocarbon receptor signaling","volume":"29","author":"Santana Machado","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"B9-20260109","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/ndt\/gfr616","article-title":"Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney disease along with an accumulation of protein-bound uraemic toxins","volume":"27","author":"Klammt","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"13","key":"B10-20260109","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med."},{"issue":"1","key":"B11-20260109","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J Am Soc Nephrol."},{"key":"B12-20260109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2016.04.007","article-title":"Atrial fibrillation in chronic kidney disease","volume":"33","author":"Voroneanu","year":"2016","journal-title":"Eur J Intern Med."},{"issue":"8","key":"B13-20260109","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","article-title":"Pharmacokinetics and dosage adjustment in patients with renal dysfunction","volume":"65","author":"Verbeeck","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"issue":"8","key":"B14-20260109","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2215\/CJN.01030120","article-title":"Adverse drug reactions in patients with CKD","volume":"15","author":"Laville","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B15-20260109","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/j.ajkd.2023.09.012","article-title":"Kidney function decline and serious adverse drug reactions in patients with CKD","volume":"83","author":"Laville","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B16-20260109","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5414\/CN108400","article-title":"Evaluating time in therapeutic range for hemodialysis patients taking warfarin","volume":"83","author":"Quinn","year":"2015","journal-title":"Clin Nephrol."},{"key":"B17-20260109","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ebiom.2016.04.013","article-title":"Chronic kidney disease, time in therapeutic range and adverse clinical outcomes in anticoagulated patients with non-valvular atrial fibrillation: observations from the SPORTIF trials","volume":"8","author":"Proietti","year":"2016","journal-title":"EBioMedicine."},{"issue":"4","key":"B18-20260109","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol."},{"issue":"10","key":"B19-20260109","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2215\/CJN.03980609","article-title":"Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients","volume":"4","author":"Barreto","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B20-20260109","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/ndt\/gfp592","article-title":"Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease","volume":"25","author":"Liabeuf","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"B21-20260109","doi-asserted-by":"crossref","first-page":"117498","DOI":"10.1016\/j.cca.2023.117498","article-title":"Quantitative determination of plasma free and total concentrations of antivitamin K drugs using a new sensitive and rapid LC-MS\/MS method: application in hemodialysis patients","volume":"548","author":"Mernissi","year":"2023","journal-title":"Clin Chim Acta."},{"key":"B22-20260109","doi-asserted-by":"crossref","first-page":"122234","DOI":"10.1016\/j.jchromb.2020.122234","article-title":"Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: an application for describing their accumulation kinetic profile in a context of acute kidney injury","volume":"1152","author":"Andr\u00e9","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"issue":"4","key":"B23-20260109","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1002\/cpz1.762","article-title":"Measurement of homocitrulline, A carbamylation \u2013 derived product, in serum and tissues by LC \u2013 MS\/MS","volume":"3","author":"Jaisson","year":"2023","journal-title":"Curr Protoc."},{"issue":"6","key":"B24-20260109","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"J Pers Soc Psychol."},{"issue":"3","key":"B26-20260109","first-page":"1","article-title":"mice: multivariate imputation by chained equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw."},{"issue":"4","key":"B28-20260109","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF03190876","article-title":"The role of the protein-binding on the mode of drug action as well the interactions with other drugs","volume":"33","author":"Tesseromatis","year":"2008","journal-title":"Eur J Drug Metab Pharmacokinet."},{"issue":"5","key":"B29-20260109","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1053\/j.ajkd.2007.12.035","article-title":"A review of albumin binding in CKD","volume":"51","author":"Meijers","year":"2008","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"B30-20260109","doi-asserted-by":"crossref","first-page":"822","DOI":"10.5858\/1999-123-0822-FDM","article-title":"Free drug measurements. when and why? an overview","volume":"123","author":"Soldin","year":"1999","journal-title":"Arch Pathol Lab Med."},{"issue":"1","key":"B31-20260109","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/fcp.12088","article-title":"Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study","volume":"29","author":"B\u00e9nard-Laribi\u00e8re","year":"2015","journal-title":"Fundam Clin Pharmacol."},{"issue":"4","key":"B32-20260109","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B33-20260109","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2014.11.004","article-title":"Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study","volume":"65","author":"Limdi","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B34-20260109","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/cts.13084","article-title":"Consequences of oral antithrombotic use in patients with chronic kidney disease","volume":"14","author":"Laville","year":"2021","journal-title":"Clin Transl Sci."},{"key":"B35-20260109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2017.12.001","article-title":"Protein carbamylation: chemistry, pathophysiological involvement, and biomarkers","volume":"84","author":"Jaisson","year":"2018","journal-title":"Adv Clin Chem."},{"issue":"5","key":"B36-20260109","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/clpt.1980.87","article-title":"Plasma protein carbamylation and decreased acidic drug protein binding in uremia","volume":"27","author":"Erill","year":"1980","journal-title":"Clin Pharmacol Ther."},{"issue":"10","key":"B37-20260109","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00726-023-03306-0","article-title":"Comparison of homocitrulline and carbamylated albumin as biomarkers of carbamylation reactions in hemodialyzed patients","volume":"55","author":"Lenglet","year":"2023","journal-title":"Amino Acids."},{"issue":"1","key":"B38-20260109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12882-024-03619-6","article-title":"Comparative CKD risk prediction using homocitrulline and carbamylated albumin: two circulating markers of protein carbamylation","volume":"25","author":"Awwad","year":"2024","journal-title":"BMC Nephrol."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:59:29Z","timestamp":1786478369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000862"}},"subtitle":["An Example with Oral Anticoagulants"],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000862","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"2024-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}